Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details)

v3.19.1
Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Disaggregation of Revenue [Line Items]    
Total Revenue $ 8,545 $ 4,152
Seattle Genetics    
Disaggregation of Revenue [Line Items]    
Total Revenue 925 308
AstraZeneca    
Disaggregation of Revenue [Line Items]    
Total Revenue 6,020 2,545
Servier    
Disaggregation of Revenue [Line Items]    
Total Revenue 1,600 1,208
Other    
Disaggregation of Revenue [Line Items]    
Total Revenue $ 0 $ 91